Clonal Hematopoiesis of Immunological Significance (CHIS)

A

Assistance Publique - Hôpitaux de Paris

Status

Not yet enrolling

Conditions

Inflammation
Myeloproliferative Disorders
Immune System Diseases
Leukemia
Monoclonal Gammopathy of Undetermined Significance
Myelodysplastic Syndromes
Autoimmune Diseases
Clonal Hematopoiesis of Indeterminate Potential
Leukemia Myelomonocytic Chronic
Hematopoiesis Clonal
Myelodysplastic-Myeloproliferative Diseases
Lymphoma
Autoinflammatory Diseases
Vexas Syndrome
Lymphoproliferative Disorders
Hematologic Diseases

Treatments

Other: observational cohort study

Study type

Observational

Funder types

Other

Identifiers

NCT05969821
APHP221121

Details and patient eligibility

About

Ambispective, national, multicenter observational cohort study aimed at characterizing the satellite dysimmune manifestations of clonal hematopoiesis, including Vexas (Vacuoles, E1 enzyme, X-linked, Autoinflammatory and Somatic) syndrome.

Full description

The clinical spectrum of dysimmune manifestations associated with blood diseases is wide. The pathophysiology of these manifestations is not well understood and their management is poorly codified. This observational cohort aims to list the different clinical pictures, the therapeutic management and the prognosis of patients according to the type of dysimmune manifestations and the type of hemopathy. We wish to have an inventory of the demographic, genetic, clinical and evolutionary data of patients with an inflammatory manifestation associated or not with a myeloid or lymphoid hemopathy. This will make it possible to establish quantitative data on the morbidity and mortality of these rare diseases and to propose therapeutic trials for the most serious patients.

Enrollment

1,000 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age >=18 years old
  • Confirmed dysimmune manifestations: clinical or biological abnormality or systemic disease
  • Presence or absence of myeloid or lymphoid blood disease according to World Health Organization (WHO) classification

Exclusion criteria

  • Persons benefiting from special protection: adults under guardianship and curatorship; people hospitalized without their consent and not protected by law; persons deprived of liberty.
  • Persons not affiliated to the social security system

Trial design

1,000 participants in 1 patient group

Dysimmune manifestations with or without clonal hematopoiesis
Description:
Dysimmune manifestations with or without clonal hematopoiesis
Treatment:
Other: observational cohort study

Trial contacts and locations

0

Loading...

Central trial contact

Arsene MEKINIAN, MD PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems